Strides Pharma Science announced that its step]down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the United States Food & Drug Administration (US FDA).
The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)